SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+51.32%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$357M
AUM Growth
+$357M
(+10%)
Cap. Flow
-$27M
Cap. Flow
% of AUM
-7.57%
Top 10 Holdings %
Top 10 Hldgs %
41.79%
Holding
95
New
30
Increased
9
Reduced
31
Closed
21
Top Buys
| 1 |
Avidity Biosciences
RNA
|
$12.5M |
| 2 |
C4 Therapeutics
CCCC
|
$11.7M |
| 3 |
Solid Biosciences
SLDB
|
$9.73M |
| 4 |
Perspective Therapeutics
CATX
|
$9.65M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$5.98M |
Top Sells
| 1 |
Mersana Therapeutics
MRSN
|
$15.5M |
| 2 |
MacroGenics
MGNX
|
$11.5M |
| 3 |
Medtronic
MDT
|
$11.1M |
| 4 |
Sanofi
SNY
|
$10.9M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
$7.59M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Modular Medical
MODD
$39.7M
| $1.67M | 0.46% |
+900,000
| New | +$1.67M |
|
52
Terns Pharmaceuticals
TERN
$651M
| $1.64M | 0.46% |
250,551
-266,448
| -52% | -$1.75M |
|
53
Viking Therapeutics
VKTX
$3.02B
| $1.64M | 0.46% |
+20,000
| New | +$1.64M |
|
54
Amylyx Pharmaceuticals
AMLX
$877M
| $1.42M | 0.39% |
+500,000
| New | +$1.42M |
|
55
Corbus Pharmaceuticals
CRBP
$121M
| $1.25M | 0.35% |
+31,980
| New | +$1.25M |
|
56
Fractyl Health
GUTS
$66.2M
| $1.23M | 0.34% |
+166,666
| New | +$1.23M |
|
57
89bio
ETNB
$1.37B
| $1.07M | 0.3% |
92,298
-66,421
| -42% | -$773K |
|
|
ABVX
58
Abivax
ABVX
$6.32B
| $1.07M | 0.3% |
+75,000
| New | +$1.07M |
|
59
Zura Bio
ZURA
$132M
| $844K | 0.23% |
328,504
-134,493
| -29% | -$346K |
|
60
Karyopharm Therapeutics
KPTI
$61.4M
| $843K | 0.23% |
558,466
-3,489
| -0.6% | -$5.28K |
|
61
Geron
GERN
$893M
| $825K | 0.23% |
+250,000
| New | +$825K |
|
|
MTEM
62
DELISTED
Molecular Templates, Inc.
MTEM
| $794K | 0.22% |
354,608
| – | – |
|
63
Adicet Bio
ACET
$60.8M
| $779K | 0.22% |
+331,279
| New | +$779K |
|
64
Mineralys Therapeutics
MLYS
$1.94B
| $735K | 0.2% |
+56,944
| New | +$735K |
|
65
Aligos Therapeutics
ALGS
$75.1M
| $642K | 0.18% |
655,515
-12,997
| -2% | -$12.7K |
|
66
Relmada Therapeutics
RLMD
$48.8M
| $462K | 0.13% |
99,379
-621
| -0.6% | -$2.89K |
|
67
Erasca
ERAS
$406M
| $461K | 0.13% |
+223,845
| New | +$461K |
|
68
Structure Therapeutics
GPCR
$1.14B
| $429K | 0.12% |
+10,000
| New | +$429K |
|
69
Rezolute
RZLT
$630M
| $388K | 0.11% |
151,985
-5,100
| -3% | -$13K |
|
70
VYNE Therapeutics
VYNE
$8.09M
| $265K | 0.07% |
+86,383
| New | +$265K |
|
71
Elutia
ELUT
$84.4M
| $248K | 0.07% |
+78,580
| New | +$248K |
|
72
Immunome
IMNM
$892M
| $185K | 0.05% |
+7,489
| New | +$185K |
|
|
73
Rocket Pharmaceuticals, Inc. Warrant
RCKTW
$4.17M
| $31.4K | 0.01% |
104,828
| – | – |
|
|
MRTX
74
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
0
| – | – |
|
|
CBAY
75
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-218,975
| Closed | -$5.17M |
|